New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 7, 2021 - Alexion announced the FDA approval of Ultomiris (ravulizumab-cwvz), for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Download PDF
Return to publications
